Anti-angiogenic effect of bortezomib in patients with multiple myeloma

Acta Haematol. 2005;114(3):170-3. doi: 10.1159/000087894.
No abstract available

MeSH terms

  • Adult
  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Boronic Acids / therapeutic use*
  • Bortezomib
  • Female
  • Humans
  • Male
  • Microcirculation / drug effects
  • Microcirculation / pathology
  • Middle Aged
  • Multiple Myeloma / blood supply*
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / metabolism
  • Neovascularization, Pathologic / drug therapy*
  • Neovascularization, Pathologic / metabolism
  • Neovascularization, Pathologic / pathology
  • Protease Inhibitors / therapeutic use
  • Pyrazines / therapeutic use*
  • Ribonuclease, Pancreatic / metabolism
  • Vascular Endothelial Growth Factor A / metabolism

Substances

  • Antineoplastic Agents
  • Boronic Acids
  • Protease Inhibitors
  • Pyrazines
  • Vascular Endothelial Growth Factor A
  • Bortezomib
  • angiogenin
  • Ribonuclease, Pancreatic